Agonist News and Research

RSS

Alizé Pharma completes two Phase I clinical trials of AZP-531 in healthy volunteers, obese subjects

Alizé Pharma SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, announces today the completion of two Phase I clinical trials with its unacylated ghrelin analog AZP-531 in 76 healthy volunteers and overweight or obese subjects.

10 Dec 2014

Triple hormone reduces body weight, improves insulin sensitivity

Recently, the researchers had constructed several single molecules with dual hormone action. Now, for the first time, the researchers succeeded in designing a substance that combines three metabolically active hormone components (GLP-1, GIP and glucagon) and offers unmatched potency to fight metabolic diseases in pre-clinical trials.

9 Dec 2014

Non-ergot derived dopamine agonists may be safe for the heart

Non-ergot derived dopamine agonists used to treat Parkinson's disease may be safe for the heart, according to preliminary research presented at EuroEcho-Imaging 2014 by Dr Hilal Erken Pamukcu, cardiologist at Ankara Diskapi Education and Research Hospital in Turkey.

4 Dec 2014

AcelRx Pharmaceuticals' Zalviso device gets CE Mark approval

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device.

2 Dec 2014

Fenofibrate benefits in diabetic retinopathy mediated through PPARα

Peroxisome proliferator–activated receptor α exerts protective effects on retinal pericytes, shows research that explains why fenofibrate is protective against diabetic retinopathy.

1 Dec 2014

Inhibin B plus baseline LH levels aids hypogonadotropic hypogonadism diagnosis in boys

Researchers recommend measuring inhibin B concentration in combination with basal luteinising hormone as a first-line test to discover the underlying cause of delayed puberty in boys.

1 Dec 2014

Clementia's palovarotene receives FDA Fast Track designation for FOP treatment

Clementia Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).

1 Dec 2014

SLU researcher discovers way to block pain pathway

In research published in the medical journal Brain, Saint Louis University researcher Daniela Salvemini, Ph.D. and colleagues within SLU, the National Institutes of Health and other academic institutions have discovered a way to block a pain pathway in animal models of chronic neuropathic pain including pain caused by chemotherapeutic agents and bone cancer pain suggesting a promising new approach to pain relief.

27 Nov 2014

Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva (FOP).

21 Nov 2014

Protein complex plays key role in detecting tumor cells, promotes anti-tumor response

A recently discovered protein complex known as STING plays a crucial role in detecting the presence of tumor cells and promoting an aggressive anti-tumor response by the body's innate immune system, according to two separate studies published in the Nov. 20 issue of the journal Immunity.

21 Nov 2014

UCSD researchers implicate new gene in idiopathic or non-syndromic autism

With the help of mouse models, induced pluripotent stem cells (iPSCs) and the "tooth fairy," researchers at the University of California, San Diego School of Medicine have implicated a new gene in idiopathic or non-syndromic autism. The gene is associated with Rett syndrome, a syndromic form of autism, suggesting that different types of autism spectrum disorder (ASD) may share similar molecular pathways.

11 Nov 2014

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.

11 Nov 2014

LAMA/LABA combination better than monotherapy for severe COPD

Combination treatment with umeclidinium bromide and vilanterol offers clinically meaningful improvements over tiotropium monotherapy for patients with moderate-to-very severe chronic obstructive pulmonary disease, study data show.

31 Oct 2014

Combination therapy beneficial for COPD patients

Research published in JAMA supports the use of a combination of long-acting β-agonists and inhaled corticosteroids in patients with chronic obstructive pulmonary disease.

31 Oct 2014

Clementia initiates Phase 2 extension study of palovarotene in FOP patients

Clementia Pharmaceuticals, Inc. announced today the initiation of a Phase 2 extension study of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling genetic disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and new abnormal bone formation.

27 Oct 2014

Study shows that obese children may mistake asthma symptoms, overuse rescue medications

New research shows obese children with asthma may mistake symptoms of breathlessness for loss of asthma control leading to high and unnecessary use of rescue medications. The study was published online in the Journal of Allergy and Clinical Immunology, the official scientific journal of the American Association of Allergy, Asthma and Immunology.

27 Oct 2014

Levodopa dose linked to malnutrition risk in Parkinson’s disease

The malnutrition often seen in patients with Parkinson’s disease could be partly an effect of levodopa medication, research suggests.

22 Oct 2014

Obeticholic acid drug shows promise against bile acid diarrhoea

A pilot study testing a new type of drug in patients with chronic diarrhoea has shown promising effects on reducing their symptoms.

21 Oct 2014

Researchers propose new milestones to augment National Alzheimer's Plan

The U.S. Government has initiated a major effort to prevent and effectively treat Alzheimer's disease by 2025. However, a workgroup of nearly 40 Alzheimer's researchers and scientists says the research milestones in the U.S. Government's National Plan to Address Alzheimer's Disease must be broadened in scope, increased in scale, and adequately funded in order to successfully achieve this goal.

20 Oct 2014

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim today announced that Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States.

8 Oct 2014